标准三联疗法联合益生菌治疗幽门螺杆菌相关慢性胃炎临床效果研究.docVIP

标准三联疗法联合益生菌治疗幽门螺杆菌相关慢性胃炎临床效果研究 　　[摘要] 目的 探讨标准三联疗法联合益生菌治疗幽门螺杆菌相关慢性胃炎的疗效。 方法 收集2015年1～12月期间我院收治的幽门螺杆菌相关的慢性胃炎患者102例作为研究对象，按照随机数字表法分为对照组和观察组，每组51例，对照组用标准三联疗法治疗，观察组用标准三联疗法联合联合益生菌治疗，金双歧（双歧杆菌乳杆菌三联活菌片）。观察两组临床症状评分、总有效率及Hp根除率。 结果 治疗后观察组和对照组临床症状评分低于治疗前，治疗前后差异有统计学意义（P0.05）；观察组治疗后临床症状评分与对照组比较降低的更明显，差异具有统计学意义（P0.05）。观察组总有效率及Hp根除率与对照组比较更高，差异有统计学意义（P0.05）。 结论 幽门螺杆菌相关慢性胃炎患者使用标准三联疗法联合益生菌治疗疗效显著，可有效缓解患者的临床症状体征，提高临床疗效及Hp根除率，效果优于标准三联疗法。 　　[关键词] 胃炎；幽门螺杆菌；三联疗法；益生菌 　　[中图分类号] R573.1 [文献标识码] B [文章编号] 2095-0616（2016）09-226-03 　　[Abstract] Objective To explore the efficacy of Helicobacter pylori associated chronic gastritis treated with standard triple therapy combined with probiotic. Methods 102 cases with chronic gastritis associated with Helicobacter pylori were collected as research subjects，all the patients were selected from January 2015 to December 2015 in our hospital， and randomly divided into the control group and the observation group， there were 51 cases in each group， the patients in control group were given standard triple therapy， the patients in observation group were given probiotics joint with standard triple therapy and Jinshuangqi （Bifidobacterium Lactobacillus triple viable tablet）.The clinical symptom score，total efficiency and Hp eradication rate of two groups were compared. Results The clinical symptom score of the observation group and the control group after treatment was significantly lower than before treatment， the difference was statistically significant（P0.05）.After treatment the decreased degree of the clinical symptom score of the observation group was more significantly than that of the control group， the difference was statistically significant（P0.05）.The total effective rate and Hp eradication rate of the observation group were higher than that of control group，the difference was statistically significant（P0.05）. Conclusion Helicobacter pylori related chronic gastritis patients which treated with standard triple therapy combined with a probiotic therapy